Lupin launches ‘Humrahi’ unique patient support program for diabetes management

03 Oct 2023 Evaluate

Lupin has launched Humrahi, a patient support program, ushering in a new era of diabetes management through adherence, behavior and transformation. Humrahi, translating to ‘Companion’ is a guide in the journey of diabetes management. It offers comprehensive support by emphasizing the critical aspects of therapy adherence through personalized diet counseling, medication assistance, and tailored lifestyle modifications, all under the guidance of healthcare professionals. 

Further, Humrahi empowers patients with the knowledge and skills necessary for precise insulin injection techniques, thereby enabling them to effectively manage blood sugar levels and experience an enhanced quality of life. 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2112.95 3.95 (0.19%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×